Graves Disease Clinical Trial
Official title:
Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy
| NCT number | NCT00796913 |
| Other study ID # | RISG2 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | January 7, 2008 |
| Est. completion date | May 15, 2015 |
| Verified date | January 2019 |
| Source | Aalborg Universitetshospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
ATD therapy for Graves' disease is one of the commonly used options for therapy of the hyperthyroidism. The investigators study how to optimally keep patients in remission.
| Status | Completed |
| Enrollment | 139 |
| Est. completion date | May 15, 2015 |
| Est. primary completion date | May 15, 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Graves hyperthyroidism in remission after ATD Exclusion Criteria: - Age < 18, severe concomitant disease |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Aalborg Universitetshospital |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Relapse of hyperthyroidism | 2 years | ||
| Secondary | Reoccurrence of TSH-receptor autoimmunity | 2 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
| Completed |
NCT02973802 -
ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
|
Phase 1 | |
| Completed |
NCT02491567 -
DNA Methylation and Autoimmune Thyroid Diseases
|
||
| Terminated |
NCT01320813 -
Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy
|
N/A | |
| Completed |
NCT00432146 -
Effect of Lugol's Solution in the Patients With Graves' Disease
|
N/A | |
| Recruiting |
NCT06081439 -
Validating Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
| Recruiting |
NCT05635266 -
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04135573 -
The Relationship Between NK Cell and Graves' Disease
|
||
| Recruiting |
NCT06134219 -
Course for Brain Fatigue After Graves' Disease Controlled Study
|
N/A | |
| Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
| Recruiting |
NCT05678374 -
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
| Completed |
NCT03009357 -
Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
|
||
| Recruiting |
NCT05510609 -
Three-dimensional Ultrasonography Thyroid Volume Measurement.
|
N/A | |
| Recruiting |
NCT05907668 -
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
|
Phase 2 | |
| Recruiting |
NCT06275373 -
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
|
||
| Recruiting |
NCT03303053 -
Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism
|
Phase 3 | |
| Recruiting |
NCT05461820 -
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
|
Phase 4 | |
| Recruiting |
NCT06309316 -
The Impact of Person Centred Care (PCC) in Grave's Disease
|
N/A | |
| Completed |
NCT00782366 -
Predictive Genetic Risk Assessment Trial
|
N/A |